142 related articles for article (PubMed ID: 30690867)
1. Checkpoint inhibitors in the emergency department.
Bachmeier CA; Morton A
Emerg Med Australas; 2019 Apr; 31(2):288-289. PubMed ID: 30690867
[No Abstract] [Full Text] [Related]
2. Diabetic ketoacidosis induced by a single dose of pembrolizumab.
Maamari J; Yeung SJ; Chaftari PS
Am J Emerg Med; 2019 Feb; 37(2):376.e1-376.e2. PubMed ID: 30361152
[TBL] [Abstract][Full Text] [Related]
3. Diabetic ketoacidosis following immunotherapy for lung cancer.
Skorpen PK; Margull J
Tidsskr Nor Laegeforen; 2019 Feb; 139(4):. PubMed ID: 30808100
[No Abstract] [Full Text] [Related]
4. Fulminant diabetes due to immune checkpoint inhibitors in the emergency department.
Peyrony O; Ellouze S; Fontaine JP; Mohamadou I; Zafrani L
Am J Emerg Med; 2020 Feb; 38(2):408.e3-408.e4. PubMed ID: 31759780
[TBL] [Abstract][Full Text] [Related]
5. Diarrhoea during checkpoint blockade, not always colitis.
Koldenhof JJ; Suijkerbuijk KPM
Eur J Cancer; 2017 Dec; 87():216-218. PubMed ID: 28993041
[No Abstract] [Full Text] [Related]
6. Rapid granulomatosis with polyangiitis induced by immune checkpoint inhibition.
van den Brom RR; Abdulahad WH; Rutgers A; Kroesen BJ; Roozendaal C; de Groot DJ; Schröder CP; Hospers GA; Brouwer E
Rheumatology (Oxford); 2016 Jun; 55(6):1143-5. PubMed ID: 27069016
[No Abstract] [Full Text] [Related]
7. Combined checkpoint inhibitor therapy causing diabetic ketoacidosis in metastatic melanoma.
Changizzadeh PN; Mukkamalla SKR; Armenio VA
J Immunother Cancer; 2017 Dec; 5(1):97. PubMed ID: 29254501
[TBL] [Abstract][Full Text] [Related]
8. Hypothyroid ataxia complicating monoclonal antibody therapy.
Badran A; Moran C; Coles AJ
Pract Neurol; 2017 Dec; 17(6):482-484. PubMed ID: 28778931
[TBL] [Abstract][Full Text] [Related]
9. PD-1 inhibitor induced alopecia areata.
Guidry J; Brown M; Medina T
Dermatol Online J; 2018 Dec; 24(12):. PubMed ID: 30677804
[TBL] [Abstract][Full Text] [Related]
10. Lichen planus in a patient treated with pembrolizumab for metastatic malignant melanoma.
Denny J; Chong H; Akhras V
Clin Exp Dermatol; 2018 Apr; 43(3):354-356. PubMed ID: 29222829
[No Abstract] [Full Text] [Related]
11. Checkpoint Inhibitor-Induced Hemorrhagic Gastritis with Pembrolizumab.
Rao BB; Robertson S; Philpott J
Am J Gastroenterol; 2019 Feb; 114(2):196. PubMed ID: 30353060
[No Abstract] [Full Text] [Related]
12. Checkpoint inhibitor-induced sarcoid reaction mimicking bone metastases.
Jespersen H; Bjursten S; Ny L; Levin M
Lancet Oncol; 2018 Jun; 19(6):e327. PubMed ID: 29893264
[No Abstract] [Full Text] [Related]
13. Drug-associated vasculitis occurring after treatment with pembrolizumab.
Tolaymat OA; Pinkston O; Wang B; Schenk WB; Joseph RW; Mergo PJ; Berianu F
Rheumatology (Oxford); 2019 Aug; 58(8):1501-1503. PubMed ID: 30892627
[No Abstract] [Full Text] [Related]
14. Acute localised exanthematous pustulosis secondary to pembrolizumab.
Wang CY; Khoo C; McCormack CJ; Xu W; Pan Y
Australas J Dermatol; 2017 Nov; 58(4):322-323. PubMed ID: 28691194
[No Abstract] [Full Text] [Related]
15. Pembrolizumab-Induced Alopecia Areata.
Elshimy N; Blakeway E; Mitra A
Skinmed; 2019; 17(2):142-143. PubMed ID: 31145074
[No Abstract] [Full Text] [Related]
16. Immune Checkpoint Inhibitor-Induced Diabetic Ketoacidosis: A Report of Four Cases and Literature Review.
Hong AR; Yoon JH; Kim HK; Kang HC
Front Endocrinol (Lausanne); 2020; 11():14. PubMed ID: 32047478
[TBL] [Abstract][Full Text] [Related]
17. Generalised morphea induced by pembrolizumab.
Herrscher H; Tomasic G; Castro Gordon A
Eur J Cancer; 2019 Jul; 116():178-181. PubMed ID: 31202088
[No Abstract] [Full Text] [Related]
18. Refractory myasthenia gravis exacerbation triggered By pembrolizumab.
Earl DE; Loochtan AI; Bedlack RS
Muscle Nerve; 2018 Apr; 57(4):E120-E121. PubMed ID: 29193151
[No Abstract] [Full Text] [Related]
19. Fulminant type 1 diabetes mellitus associated with pembrolizumab.
Mizab Mellah C; Sánchez Pérez M; Santos Rey MD; Hernández García M
Endocrinol Diabetes Nutr; 2017 May; 64(5):272-273. PubMed ID: 29056250
[No Abstract] [Full Text] [Related]
20. Vitiligo Repigmentation with Melanoma Progression During Pembrolizumab Treatment.
Nardin C; Pelletier F; Puzenat E; Aubin F
Acta Derm Venereol; 2019 Sep; 99(10):913-914. PubMed ID: 31017249
[No Abstract] [Full Text] [Related]
[Next] [New Search]
